RX 10045 – Ocular Inflammation
RX-10045 is a proprietary molecule for the treatment of ocular diseases. It is a mimetic of Resolvin E1 (RvE1), a potent mediator of inflammatory resolution that is endogenously produced by the human body from omega-3 fatty acid.
RX-10045 may address a number of important unmet medical needs including prevention of sight-threatening corneal damage due to herpetic stromal keratitis and refractory bacterial keratitis, as well as loss of vision due to corneal neovascularization following injury or corneal transplantation. In addition, RX-10045 may offer advantages to current therapies for inflammation and pain due to cataract surgery, laser refractive procedures and other anterior segment inflammatory conditions.
The market for anti-inflammatory agents in ocular surgery is substantial, totalling approximately $800M for corticosteroid and nonsteroidal anti-inflammatory agents (NSAIDS).